Ghassan K. Abou-Alfa is an appointed physician at Memorial Sloan-Kettering Cancer Center and associate professor of the Weill Cornell Medical College in New York. Dr. Abou-Alfa specializes in the treatment of gastrointestinal malignancies with a special focus on cholangiocarcinoma, biliary cancers, and hepatocellular carcinoma. Dr. Abou-Alfa received his medical degree from the American University of Beirut, Lebanon, and completed his post-doctoral training at Yale University School of Medicine. His research is dedicated to finding novel therapies and improving the effectiveness current therapies for cholangiocarcinoma, biliary cancers and hepatocellular carcinoma, while continuing to understand the basic mechanisms of the diseases and its therapy. Dr Abou-Alfa has many publications in the field. He led on many occasions, international teams of investigators. Dr. Abou-Alfa serves as the chair of the National Cancer Institute (NCI) Task Force for Hepatobiliary Cancers and the chair of the AIDS Malignancy Consortium (AMC) Non-AIDS Defining Malignancies (NADC) Liver/GI Task Force. Dr Abou-Alfa also co-chairs the hepatobiliary group of the Alliance cooperative group, and is a cadre member of both the gastrointestinal cancers and pharmacogenomics and population pharmacology committees. Dr Abou-Alfa who has lectured worldwide on the subject of cholangiocarcinoma, biliary cancers and hepatocellular carcinoma, is also a strong advocate for raising awareness and support for improving the outcome of patients with this disease, and enhancing oncologic education worldwide. Dr. Abou-Alfa is the co-author of 100 Questions and Answers About Biliary Cancers.